The safety and pharmacokinetics of metformin in patients with chronic liver disease
暂无分享,去创建一个
R. Day | K. Williams | G. Graham | J. Greenfield | M. Danta | Zhixin Liu | Felicity C. Smith | J. Carland | S. Stocker | H. E. Braithwaite | Shaun S. Kumar | H. Braithwaite | Tim S Cheng
[1] M. Rutter,et al. Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. , 2018, Health technology assessment.
[2] C. Zauner,et al. Acid-base disorders in liver disease. , 2017, Journal of hepatology.
[3] Matthew J. Crowley,et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease , 2017, Annals of Internal Medicine.
[4] R. Day,et al. The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus. , 2015, British journal of clinical pharmacology.
[5] T. Therneau,et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes , 2014, Hepatology.
[6] M. Adeva-Andany,et al. Comprehensive review on lactate metabolism in human health. , 2014, Mitochondrion.
[7] F. Bendtsen,et al. Lactate metabolism in chronic liver disease , 2013, Scandinavian journal of clinical and laboratory investigation.
[8] A. R. Rätz Bravo,et al. Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations , 2013, European Journal of Clinical Pharmacology.
[9] R. Day,et al. The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis , 2013, Drug Safety.
[10] R. Day,et al. Population Pharmacokinetics of Metformin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus: Simulation of Doses According to Renal Function , 2013, Clinical Pharmacokinetics.
[11] J. D. del Campo,et al. Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy , 2012, PloS one.
[12] R. Day,et al. Metformin therapy in patients with chronic kidney disease , 2012, Diabetes, obesity & metabolism.
[13] Stephen Colagiuri,et al. Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement , 2012, The Medical journal of Australia.
[14] G. Bray,et al. Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study , 2012, Diabetes Care.
[15] E. Vicaut,et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. , 2011, The Journal of clinical endocrinology and metabolism.
[16] R. Day,et al. Clinical Pharmacokinetics of Metformin , 2011, Clinical pharmacokinetics.
[17] B. Astor,et al. Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study , 2010, International journal of epidemiology.
[18] M. L. de la Mata,et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa‐2a plus ribavirin , 2009, Hepatology.
[19] J. Hoofnagle,et al. Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis , 2009, Alimentary pharmacology & therapeutics.
[20] G. Jung,et al. Model for end-stage liver disease , 2008, Der Chirurg.
[21] Shari Bolen,et al. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus , 2007, Annals of Internal Medicine.
[22] V. Alves,et al. Combination of N‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[23] M. Matsuda,et al. Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation , 2007, Diabetes.
[24] W. Kim,et al. The model for end‐stage liver disease (MELD) , 2007, Hepatology.
[25] Keith G. Tolman,et al. Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease , 2007 .
[26] B. Phypers,et al. Lactate physiology in health and disease , 2006 .
[27] J. Kraut,et al. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[28] H. El‐Serag,et al. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. , 2004, Gastroenterology.
[29] A. Holstein,et al. Clinical implications of hepatogenous diabetes in liver cirrhosis , 2002, Journal of gastroenterology and hepatology.
[30] Marco Zoli,et al. Metformin in non-alcoholic steatohepatitis , 2001, The Lancet.
[31] A. Morris,et al. Contraindications to metformin therapy in patients with Type 2 diabetes—a population‐based study of adherence to prescribing guidelines , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[32] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[33] G. Reaven,et al. Plasma lactate concentration in obesity and type 2 diabetes. , 1993, Diabete & metabolisme.
[34] P. Marchetti,et al. Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients. , 1990, Diabete & metabolisme.
[35] P. Jansson,et al. Evidence for lactate production by human adipose tissue in vivo , 1990, Diabetologia.
[36] M. Eggstein,et al. Definition of clinically relevant lactic acidosis in patients with internal diseases. , 1983, American journal of clinical pathology.
[37] H Connor,et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. , 1981, British journal of clinical pharmacology.
[38] P. Woll,et al. Lactate elimination in man: effects of lactate concentration and hepatic dysfunction , 1979, European journal of clinical investigation.
[39] G. Franceschini,et al. Disposition of metformin (N,N‐dimethylbiguanide) in man , 1978, Clinical pharmacology and therapeutics.
[40] L. Hermansen,et al. Production and removal of lactate during exercise in man. , 1972, Acta physiologica Scandinavica.
[41] A. Blumentals,et al. Acid-base disturbances in patients with cirrhosis of the liver. , 1967, Medicine.
[42] J. Lalau,et al. Establishment of a Database of Metformin Plasma Concentrations and Erythrocyte Levels in Normal and Emergency Situations , 2011, Clinical drug investigation.
[43] P. Marathe,et al. Steady-State Pharmacokinetics of a Novel Extended-Release Metformin Formulation , 2005, Clinical pharmacokinetics.
[44] K. Johansen. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. , 1999, Diabetes care.
[45] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .